One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity
Methoxyflurane: a promising non-intravenous, non-opioid analgesic
Russia's health workers complicit in abducting Ukraine's children
Cerebral palsy: an update on its early detection – Authors' reply
The need for metabolic health stratification in global obesity forecasts
The need for metabolic health stratification in global obesity forecasts – Authors' reply
The diabetic foot after SWHSI-2: healing is not one size fits all
The diabetic foot after SWHSI-2: healing is not one size fits all – Authors' reply
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
